Immune to Cancer: The CRI Blog



Rational Combinations 360° Conference Will Feature Two of CRI’s Leading Scientists

As cancer immunotherapies receive approval from the FDA at an increasing rate, the next step is in drug combinations. They are already being tested in a wide range of cancers, but which combination immunotherapy is best for which patient with which tumor type?

The inaugural Rational Combinations 360° is a novel two-day forum on June 23-24, 2016, that will provide the most up-to-date progress on combination immunotherapy development, from business aspects to clinical advances to scientific data, taking place at the Park Lane Hotel in New York, NY. Axel Hoos, MD, PhD, and Patrick Hwu, MD—members of the CRI Scientific Advisory Council (SAC)—will join more than 30 speakers from academia, biopharmaceutical companies, and the investment community in this premier event that takes place near the end of CRI’s fourth annual Cancer Immunotherapy Month™.

“The business aspect of rational immunotherapy combinations—whom to partner with, whom to invest in, and the clinical question of how to increase the response rate while decreasing toxicity—are vital to accelerating immuno-oncology and bringing treatments to more patients,” said Axel Hoos, MD, PhD “Rational Combinations 360° will deal with the aspects of drug development that are relevant to industry, including prioritizing combination approaches, clinical trial design methods, partnering strategies, and the pricing and reimbursement landscape.”

Dr. Hoos, who is also the co-chair of the Cancer Immunotherapy Consortium Steering Committee, a CRI think-tank dedicated to late-stage clinical development and drug approval, and senior vice president for oncology research and development at GlaxoSmithKline, is speaking on the methodology regarding advancing combinations, and will also be on a panel discussion concerning industry partnering strategies, all on June 23. Dr. Hoos was also involved in designing the conference, as was Michael Kalos, PhD, a member of our SAC, a former CRI postdoctoral fellow, and now chief scientific officer at Eli Lilly.

Patrick Hwu, MD, the head of the division of cancer medicine at The University of Texas MD Anderson Cancer Center, will give the keynote presentation, “Next Generation of Combination Immunotherapy,” during the morning session on June 24.

Learn more about this conference and register today—and use the code CRI20 to receive a 20% discount on registration.

– See more at:

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.